A Case For Market-Based Costs In Determining Cost Effectiveness: The Hepatitis C Example

To summarize results of recently published HCV cost-effectiveness studies assessing new direct-acting antivirals (DAAs) from the payer perspective, and determine the extent to which the models integrated established methodological guidelines for utilizing market-based pricing (rather than list pricing). We conducted a structured search of the health economic literature to identify studies, abstracts, and health technology assessments (HTAs) that...